BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84 6. Fentiman IS, Howell A, Hamed H, Lee SM, Ranson M, Wall J, Chaudary MA, Ash CM, Gregory WM, Sellwood RA, et al.: A con- trolled trial of adjuvant tamoxifen, with or without pred- nisolone, in post-menopausal women with operable breast cancer. Br J Cancer 1994, 70(4):729-731. 7. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH Jr, Windschitl HE, Pfeifle DM, Etzell PS, Gerstner JG, Long HJ, et al.: A double- blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer 1991, 68(1):34-39. 8. Patel SR, Kvols LK, Hahn RG, Windschitl H, Levitt R, Therneau T: A phase II randomized trial of megestrol acetate or dexameth- asone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer 1990, 66(4):655-658. 9. DiMartino L, Demontis B, Mitchell IP, Hayward SW, Deshpande N: A randomized clinical trial to investigate the usefulness of the addition of prednisolone to tamoxifen as adjuvants to mas- tectomy in primary breast cancer patients with a high risk of recurrence: a preliminary report. Anticancer Res 1991, 11(2):869-872. 10. Macbeth F, Gregor A, Cottier B: A randomised study of meges- trol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer 1994, 11(Supplement 1):334. 11. Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, Botet J, Oderman P, Murray P: A randomized trial of intrahe- patic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of meta- static colorectal cancer. Cancer 1992, 69(2):327-334. 12. Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ: Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and pred- nisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer 1990, 65(2):200-206. 13. Adjuvant ovarian ablation versus CMF chemotherapy in pre- menopausal women with pathological stage II breast carci- noma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet 1993, 341(8856):1293-1298. 14. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svanin- ger G, Korner U, Gulich M, Karrefors I, Norli B, et al.: Anti-inflam- matory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994, 54(21):5602-5606. 15. Goldenberg IS: Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group. Cancer 1969, 23(1):109-112. 16. Ramirez G, Klotz J, Strawitz JG, Wilson WL, Cornell GN, Madden RE, Minton JP: Combination chemotherapy in breast cancer: a randomized study of 4 versus 5 drugs. Oncology 1975, 32(3–4):101-108. 17. Brambilla C, De Lena M, Bonadonna G: Combination chemother- apy with adriamycin (NSC-123127) in metastatic mammary carcinoma. Cancer Chemother Rep 1974, 58(2):251-253. 18. Gaertner RA, Lewison EF, Finney GG Jr, Montague AC: Combined hormone therapy in advanced breast cancer. Triple-blind study of 68 patients treated with dromostanolone and fluor- ometholone. Johns Hopkins Med J 1968, 123(3):138-141. 19. Dao TL, Tan E, Brooks V: A comparative evaluation of adrena- lectomy and cortisone in the treatment of advanced mam- mary carcinoma. Cancer 1961, 14:1259-1265. 20. Reitemeier RJ, Moertel CG, Hahn RG: Comparative evaluation of palliation with fluorometholone (NSC-33001), 5-fluorouracil (NSC-19893), and combined fluorometholone and 5-fluor- ouracil in advanced gastrointestinal cancer. Cancer Chemother Rep 1967, 51(2):77-80. 21. Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, DeWys W, Perlia C, Rice MA: Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer 1982, 50(7):1235-1244. 22. Talley RW, Brennan MJ, Vaitkevicius VK, Sandiego EL, Reed ML, Leighton GA: Comparison of 6-Alpha-Methyl-9-Alpha-Fluoro- 17-Acetoxy-21-Deoxyprednisolone with Fluoxymesterone and Methylprednisolone in Treatment of Metastatic Breast Cancer. Cancer 1964, 17:1063-1066. 23. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batz- dorf U, Brooks WH, Hunt WE, Mealey J Jr, Odom GL, et al.: Com- parisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiother- apy for the treatment of malignant glioma. Cancer Treat Rep 1983, 67(2):121-132. 24. Stewart JF, Rubens RD, King RJ, Minton MJ, Steiner R, Tong D, Winter PJ, Knight RK, Hayward JL: Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer. Eur J Cancer Clin Oncol 1982, 18(12):1307-1314. 25. Rossi A, Brambilla C, Bonadonna G: Controlled study with 1-phe- nylalanine mustard (l-PAM) and 5-fluorouracil (5-FU) plus or minus prednisone in advanced breast cancer. Tumori 1976, 62(2):193-196. 26. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974, 33(6):1607-1609. 27. Horton J, Olson KB, Hosley HF: Corticosteroids and fluorouracil toxicity. Arch Intern Med 1966, 117(6):775-777. 28. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bon- tenbal M, Awada A, Selleslags J, Van Vreckem A, et al.: Corticoster- oids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the Euro- pean Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997, 15(9):3149-3155. 29. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH: Effect of high-dose dexamethasone in carcinomatous metastatic spi- nal cord compression treated with radiotherapy: a ran- domised trial. Eur J Cancer 1994, 30A(1):22-27. 30. Della Cuna GR, Pellegrini A, Piazzi M: Effect of methylpred- nisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989, 25(12):1817-1821. 31. Gercovich F, Negro A, Requejo H, Morgenfeld E, Rivarola E, Pasccon G, Botto G, Marantz A, Tessler J, Elli A, et al.: 5Fluorouracil, cyclo- phosphamide and mitoxantrone (fucimix) vs fucimix-pred- nisone (pdn) for advanced breast cancer (abc). A prospective and randomized trial. Preliminar report. Proceedings of AACR 1989, 30:1014. 32. Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, de Prijck L, Collette L: Flutamide versus prednisone in patients with prostate cancer symptomatically progress- ing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001, 19(1):62-71. 33. Fossa SD, Jahnsen JU, Karlsen S, Ogreid P, Haveland H, Trovag A: High-dose medroxyprogesterone acetate versus pred- nisolone in hormone-resistant prostatic cancer. A pilot study. Eur Urol 1985, 11(1):11-16. 34. Thatcher N, Wagstaff J, Wilkinson P, Palmer M, Crowther D: Inter- mittent high-dose cyclophosphamide with and without pred- nisolone: a study of the relationships between toxicity, response and survival in metastatic lung cancer. Cancer 1982, 50(6):1051-1056. 35. Datta SN, Thomas K, Matthews PN: Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate? J Urol 1997, 158(1):175-177. 36. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbri- aco M, Horak I, Conolly M, Ding C, et al.: Prognostic significance of extent of disease in bone in patients with androgen-inde- pendent prostate cancer. J Clin Oncol 1999, 17(3):948-957. 37. Cocconi G, Bisagni G, Ceci G, Bacchi M, Boni C, Brugia M, Carpi A, Di Costanzo F, Franciosi V, Gori S, et al.: Low-dose aminogluteth- imide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1992, 10(6):984-989. 38. Jakobsen A, Frederiksen PL, Moller KA, Andersen AP, Brincker H, Dombernowsky P, Hansen PV, Hesselius I, Kjaer M: Medroxypro- Page 17 of 19 (page number not for citation purposes)